CR20120620A - Nuevas formas de rifaximina y usos de las mismas - Google Patents

Nuevas formas de rifaximina y usos de las mismas

Info

Publication number
CR20120620A
CR20120620A CR20120620A CR20120620A CR20120620A CR 20120620 A CR20120620 A CR 20120620A CR 20120620 A CR20120620 A CR 20120620A CR 20120620 A CR20120620 A CR 20120620A CR 20120620 A CR20120620 A CR 20120620A
Authority
CR
Costa Rica
Prior art keywords
new forms
rifaximine
same
rifaximin
cocrystal
Prior art date
Application number
CR20120620A
Other languages
English (en)
Inventor
Yiduo Wu
Stephan D Parent
Nathan Carl Schultheiss
Melanie Janelle Bevill
Petinka Vlahova
Travis L Houston
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of CR20120620A publication Critical patent/CR20120620A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Abstract

La presente invención se relaciona a nuevas formas de rifaximina kappa, theta, cocristal 1 de Rifaximina:piperazina y cocristal 2 de rifaximina:piperazina, métodos para hacerlas y su uso en preparaciones medicinales y métodos terapéuticos.
CR20120620A 2010-06-03 2012-12-10 Nuevas formas de rifaximina y usos de las mismas CR20120620A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35128110P 2010-06-03 2010-06-03
US35750510P 2010-06-22 2010-06-22
US36324110P 2010-07-10 2010-07-10
US36351110P 2010-07-12 2010-07-12
US36718510P 2010-07-23 2010-07-23
US41659310P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
CR20120620A true CR20120620A (es) 2014-05-23

Family

ID=45067089

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120620A CR20120620A (es) 2010-06-03 2012-12-10 Nuevas formas de rifaximina y usos de las mismas

Country Status (17)

Country Link
US (2) US8513275B2 (es)
EP (1) EP2575464A4 (es)
JP (1) JP2013527246A (es)
KR (1) KR20130086338A (es)
CN (1) CN103269587A (es)
AU (1) AU2011261283B2 (es)
BR (1) BR112012030783A2 (es)
CA (1) CA2800668A1 (es)
CR (1) CR20120620A (es)
EA (1) EA022490B1 (es)
IL (1) IL222900A (es)
MX (1) MX2012013945A (es)
NZ (2) NZ603590A (es)
SG (2) SG10201507035UA (es)
TN (1) TN2012000533A1 (es)
WO (1) WO2011153444A1 (es)
ZA (1) ZA201208770B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
MX2010009389A (es) 2008-02-25 2010-11-22 Salix Pharmaceuticals Ltd Formas de rifaximina y sus usos.
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2011225810B2 (en) * 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
ES2682965T3 (es) * 2011-02-11 2018-09-24 Salix Pharmaceuticals, Ltd. Formas de rifaximina y sus usos
EP2705042A1 (en) * 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EA201590522A1 (ru) * 2012-09-13 2015-06-30 Саликс Фармасьютикалс, Инк. Способы введения рифаксимина для снижения веса и лечения ожирения
JP2016516988A (ja) 2013-03-15 2016-06-09 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． 膣感染症を診断するための方法
AU2014229467A1 (en) 2013-03-15 2015-08-06 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections.
EA032705B1 (ru) 2013-04-12 2019-07-31 Альфасигма С.П.А. Способ лечения или предупреждения энтеропатии
ITMI20131307A1 (it) * 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
ES2742106T3 (es) * 2014-05-12 2020-02-13 Alfasigma Spa Nueva forma de cristal solvatado de rifaximina, producción, composiciones y usos de la misma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
EP1727520A2 (en) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
MX2010009389A (es) * 2008-02-25 2010-11-22 Salix Pharmaceuticals Ltd Formas de rifaximina y sus usos.
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
US20120108620A1 (en) 2012-05-03
WO2011153444A1 (en) 2011-12-08
KR20130086338A (ko) 2013-08-01
ZA201208770B (en) 2013-07-31
JP2013527246A (ja) 2013-06-27
CA2800668A1 (en) 2011-12-08
NZ710780A (en) 2017-02-24
IL222900A0 (en) 2012-12-31
EA022490B1 (ru) 2016-01-29
SG185490A1 (en) 2012-12-28
BR112012030783A2 (pt) 2015-09-29
SG10201507035UA (en) 2015-10-29
CN103269587A (zh) 2013-08-28
US20130317225A1 (en) 2013-11-28
US8815888B2 (en) 2014-08-26
EP2575464A1 (en) 2013-04-10
AU2011261283B2 (en) 2015-05-14
EP2575464A4 (en) 2013-10-02
US8513275B2 (en) 2013-08-20
IL222900A (en) 2017-11-30
NZ603590A (en) 2015-08-28
AU2011261283A1 (en) 2012-12-06
TN2012000533A1 (en) 2014-04-01
MX2012013945A (es) 2013-05-06
EA201270808A1 (ru) 2013-04-30

Similar Documents

Publication Publication Date Title
CR20120620A (es) Nuevas formas de rifaximina y usos de las mismas
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
CR20120449A (es) Formas de rifaximina y sus usos
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
ECSP15017505A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
CR20150401A (es) Formas de rifaximina y sus usos
DOP2014000043A (es) Pirimidinas anilladas sustituidas y uso de las mismas
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
DOP2015000069A (es) Piridinonas bicíclicas novedosas
BR112016012129A8 (pt) métodos para produção, expansão e purificação de células epiteliais do pigmento da retina, composição farmacêutica e uso das células
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
UY34018A (es) Derivados glucósidos y usos de los mismos
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
GT200800117A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y uso
UY34023A (es) Derivados de fenil-isoxazol y procedimiento para la preparación de los mismos
UY34082A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona,preparación de los mismos y uso terapéutico de los mismos
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
UY34273A (es) Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparación